Aberdeen Group plc Makes New Investment in ProQR Therapeutics N.V. $PRQR

Key Points

• Aberdeen Group plc has acquired 1,850,348 shares of ProQR Therapeutics, representing approximately $2.46 million and about 1.76% ownership in the company.
• ProQR Therapeutics reported a quarterly loss of ($0.14) EPS, missing the expected ($0.08) EPS, with revenue of $4.33 million against an expected $5.01 million.
• Several analysts have maintained a positive outlook for ProQR Therapeutics, with a consensus target price of $8.00 and an average rating of "Buy" for the stock.

Aberdeen Group plc acquired a new stake in ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,850,348 shares of the biopharmaceutical company's stock, valued at approximately $2,461,000. Aberdeen Group plc owned 1.76% of ProQR Therapeutics at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Northern Trust Corp increased its holdings in ProQR Therapeutics by 2,550.1% during the 4th quarter. Northern Trust Corp now owns 417,398 shares of the biopharmaceutical company's stock worth $1,106,000 after purchasing an additional 401,648 shares during the period. OneDigital Investment Advisors LLC increased its holdings in ProQR Therapeutics by 45.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 12,500 shares during the period. Millennium Management LLC increased its holdings in ProQR Therapeutics by 1,864.4% during the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock worth $7,492,000 after purchasing an additional 2,683,351 shares during the period. Woodline Partners LP purchased a new stake in ProQR Therapeutics during the 4th quarter worth about $9,426,000. Finally, Two Sigma Investments LP increased its holdings in ProQR Therapeutics by 512.8% during the 4th quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company's stock worth $1,015,000 after purchasing an additional 320,614 shares during the period. Hedge funds and other institutional investors own 32.65% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PRQR shares. Evercore ISI restated an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Chardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, August 8th. Oppenheimer dropped their price objective on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $8.00.

ProQR Therapeutics Trading Up 0.5%

Shares of NASDAQ PRQR traded up $0.01 during trading hours on Wednesday, reaching $2.21. The stock had a trading volume of 276,743 shares, compared to its average volume of 309,151. The firm has a market cap of $232.51 million, a price-to-earnings ratio of -4.80 and a beta of 0.43. ProQR Therapeutics N.V. has a fifty-two week low of $1.07 and a fifty-two week high of $4.62. The firm has a 50-day moving average of $2.15 and a 200-day moving average of $1.87.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). The firm had revenue of $4.33 million during the quarter, compared to analyst estimates of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. On average, equities analysts predict that ProQR Therapeutics N.V. will post -0.31 EPS for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).